Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.27, read 2026-11-05
Ethical passes the values gate
Price2.51 USD
Fair valueUnder review
Ethical score93.6/100
Our investment reviews on this name
2026-10-21Read Markdown2.71-7.4% to today ✓Accumulation gives way to Markdown after a 13% slide in 3 weeks
2026-10-02Read Accumulation3.12-19.6% to today Markup gives way to Accumulation after a 7% rise in 5 weeks
2026-08-26Read Markup2.92-14.0% to today Distribution gives way to Markup after a 5% rise in 8 weeks
2026-07-02Read Distribution2.78-9.5% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CuriosityStream Inc. holds its Markdown at $2.51. The statistical read favours the sellers, held for 33 days.
As held on the ledger · 2026-11-06
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 33 days
Price at the screen
$2.51
Valuation
N/A trailing · 9.03 forward price to earnings
Values screen
PASS· score 93.6
Beta
1.75
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.10%
Below 33%
Interest-bearing debt is just 2.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.70%
Below 33%
Cash held in interest-bearing accounts and securities is 14.7% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
1.37%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
CuriosityStream clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 2%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CURI's ethical verdict changes
Today CURI passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.35x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Factual Streaming Trading at a Quiet Discount
Picture a small factual channel buried in the corner of the big streamers' living room. CuriosityStream sits there offering science and history programming that bigger players largely ignore, yet the shares trade at a 40% discount to our fair value with a forward multiple of just 10.7 times.
That gap looks interesting because the business clears our ethical screen and carries no debt burden worth mentioning. Revenue is flat and margins remain negative, but the low valuation already prices in a long period of stagnation rather than any heroic recovery.
Competition from larger platforms keeps the moat weak and losses could linger if subscriber additions stay muted. The median analyst target sits higher, yet execution risk in a crowded market is real. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CURI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markdown$2.54-9.3%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-10-28Markdown$2.80+3.3%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-10-21Markdown · changed$2.71-3.2%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.2% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-10-14Accumulation$2.80-10.3%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 10.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-10-02Accumulation · changed$3.12+6.8%Entry 6
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-08-26Markup · changed$2.92+14.1%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-07-25Distribution$2.56-7.7%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.7% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-07-18Distribution$2.78+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it buy, with a mean price target of $5.
2026-07-03Distribution$2.78+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Distribution$2.78Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
